IP Library Granted Patent US 7,619,102
Granted Patent B2
US 7,619,102 · App. 11/816,439 · Granted Nov 17, 2009

Purification of mupirocin

Assignee: Axellia Pharmaceuticals ApS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,619,102
App. No.
11/816,439
Granted
Nov 17, 2009
Kind
B2
Abstract

A method for purification of the antibiotic mupirocin (pseudomonic acid A) which comprises: a) Causing or allowing precipitation of mupirocin from an aqueous solution thereof; b) Recovering the precipitate; c) Dissolving the recovered precipitate in an organic solvent.

Claims (17)

1. A method for purifying mupirocin, consisting essentially of:

a) precipitating mupirocin from an aqueous solution of mupirocin by adding an acid, wherein the pH of the aqueous solution during precipitation is in the range of 2.0 to 6.0; and

b) recovering a mupirocin precipitate from the aqueous solution.

2. A method according to claim 1 , wherein the acid is selected from the group consisting of acetic acid; citric acid; sulfuric acid; and hydrochloric acid.

3. A method according to claim 1 , wherein the aqueous solution of mupirocin is a clarified fermentation broth.

4. A method according to claim 1 , wherein the mupirocin precipitate is recovered in step b) by centrifugation or filtration.

5. The method according to claim 1 , further comprising one or more additional steps selected from the group consisting of: a decolourisation step; a step for removal of hydrophilic components; a concentration step; an evaporation step; a clarification step; a water removal step; a drying step; a filtration step; an extraction step; and a crystallization step.

6. The method according to claim 3 , wherein the fermentation broth is a filtered broth.

7. The method according to claim 1 , wherein the pH is in the range of 3.5 to 5.

8. The method according to claim 1 , wherein the pH is in the range of 4.2 to 4.6.

9. The method according to claim 1 , further comprising c) dissolving the mupirocin precipitate in an organic solvent.

10. A method according to claim 9 , wherein, in step c), the organic solvent is a polar, water immiscible or moderately soluble organic solvent.

11. A method according to claim 10 , wherein the organic solvent is a ketone; an ester; an alkanol ; or a mixture comprising any combination of the foregoing solvents.

12. A method according to claim 10 , wherein the organic solvent is pure methyl isobutyl ketone.

13. The method according to claim 11 , wherein the organic solvent is methyl isobutyl ketone, ethyl acetate, n-butanol, or a combination thereof.

14. The method according to claim 9 , further comprising d) recovering mupirocin from the organic solvent.

15. A method according to claim 14 , wherein mupirocin is recovered from the solvent by crystallization, optionally after water removal from the solvent.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2012
From: XELLIA PHARMACEUTICALS APS
To: SYNGEN BIOTECH CO., LTD.
Reel/Frame 027853/0788 →
CHANGE OF NAME Recorded Sep 27, 2010
From: AXELLIA PHARMACEUTICALS APS
To: XELLIA PHARMACEUTICALS APS
Reel/Frame 025046/0654 →
CHANGE OF NAME Recorded Oct 24, 2008
From: ALPHARMA APS
To: AXELLIA PHARMACEUTICALS APS
Reel/Frame 021734/0997 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2008
From: BISSCHOPS, MARC ANTONIUS THEODORUS; REIJNS, TIEMEN GEERT PIETER; MATHIESEN, ANITA; AASSVEEN, LENE
To: ALPHARMA APS
Reel/Frame 020691/0678 →
Priority Claims (1)
DK 2005 00261 · Feb 21, 2005 · national
Continuity (1)
Related Publication 20080234503A1 · Sep 25, 2008